We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Healius is a diagnostics & research business based in Australia. Healius shares (HLS) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Healius has a trailing 12-month revenue of around $2.3 billion. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
Long-term investing
Our top pick for
Low-cost broker
| 52-week range | $3.585 - $5.4158 |
|---|---|
| 50-day moving average | $4.0994 |
| 200-day moving average | $4.5389 |
| Target price | $4.3 |
| PE ratio | 10.5731 |
| Dividend yield | $0.168 (5.51%) |
| Earnings per share (TTM) | $0.349 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$3.7
| 1 week (2022-06-22) | 1.93% |
|---|---|
| 1 month (2022-05-30) | -13.95% |
| 3 months (2022-03-30) | -16.48% |
| 6 months (2021-12-30) | -31.10% |
| 1 year (2021-06-30) | -20.09% |
|---|---|
| 2 years (2020-06-30) | 21.31% |
| 3 years (2019-06-28) | 22.52% |
| 5 years (2017-06-29) | 5.16% |
Valuing Healius stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Healius's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Healius's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 11x. In other words, Healius shares trade at around 11x recent earnings.
That's relatively low compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Healius's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $521.2 million (£0.0 million).
The EBITDA is a measure of a Healius's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $2.3 billion |
|---|---|
| Operating margin TTM | 20.9% |
| Gross profit TTM | $725.5 million |
| Return on assets TTM | 7.74% |
| Return on equity TTM | 11.5% |
| Profit margin | 9.24% |
| Book value | 3.347 |
| Market capitalisation | $2.1 billion |
TTM: trailing 12 months
Dividend payout ratio: 31.6% of net profits
Recently Healius has paid out, on average, around 31.6% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 5.51% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Healius shareholders could enjoy a 5.51% return on their shares, in the form of dividend payments. In Healius's case, that would currently equate to about A$0.168 per share.
While Healius's payout ratio might seem fairly standard, it's worth remembering that Healius may be investing much of the rest of its net profits in future growth.
The latest dividend was paid out to all shareholders who bought their shares by 24 March 2022 (the "ex-dividend date").
Healius's shares were split on a 511:493 basis on 22 August 2018. So if you had owned 493 shares the day before the split, the next day you would own 511 shares. This wouldn't directly have changed the overall worth of your Healius shares – just the quantity. However, indirectly, the new 3.5% lower share price could have impacted the market appetite for Healius shares which in turn could have impacted Healius's share price.
Over the last 12 months, Healius's shares have ranged in value from as little as $3.585 up to $5.4158. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Healius's is 1.047. This would suggest that Healius's shares are a little bit more volatile than the average for this exchange and represent, relatively speaking, a slightly higher risk (but potentially also market-beating returns).
Healius Limited provides facilities and support services to independent general practitioners, radiologists, and other healthcare professionals in Australia. The company operates through three segments: Pathology, Imaging, and Day Hospitals. It offers diagnostic imaging services, including X-ray, ultrasound, computerized tomography, mammography, magnetic resonance imaging, nuclear medicine, positron emission tomography, and interventional radiology; and private medical laboratory and pathology services. The company also provides cataract surgery, colonoscopy, gastroscopy, plastic and cosmetic surgery, skin, cancer removal, IVF egg collection, and gynaecological surgery services. It operates 2,335 sites, including 2,185 pathology sites; 15 day hospital sites; and 135 imaging sites. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius Limited was incorporated in 1994 and is headquartered in St Leonards, Australia.
Everything we know about the Australia Sunny Glass Group IPO, plus information on how to buy in.
Steps to owning and managing Kincora Copper shares.
Everything we know about the Dragon Mountain Gold IPO, plus information on how to buy in.
Steps to owning and managing Arcadia Minerals shares.
Steps to owning and managing Nexgen Energy shares.
Steps to owning and managing Keypath Education shares.
If you want to directly fund climate solutions a green bond is a great place to start. Here is how they work.
What's the best way to invest money in Australia? Find out about robo advisors, index funds, cryptocurrency and more in this guide.
Steps to owning and managing EBR Systems shares.
Steps to owning and managing 5E Advanced Materials shares.
